# Trading Cycle Report - 2026-06-21

**Environment**: staging
**Cycle covered**: runs 817-820
**Cycle triggered**: manual at 2026-06-21 13:25:18 UTC
**Cycle duration**: ~1m 31s (13:25:18 -> 13:26:49)
**Overall result**: 4/4 completed, 3 trades executed (1 BUY, 2 SELL), 1 HOLD, 0 failed

---

## Cycle Summary - 2026-06-21 13:25 UTC

| Agent  | Style              | Decision | Symbol | Qty | Price    | Total      | Candidates                  |
|--------|--------------------|----------|--------|-----|----------|------------|-----------------------------|
| Ray    | Risk Parity        | SELL     | PG     | 41  | $150.38  | $6,165.58  | JNJ, KO, EMR                |
| George | Contrarian Macro   | BUY      | C      | 48  | $143.06  | $6,866.88  | CCJ, C, LNG                 |
| Warren | Value Investor     | HOLD     | -      | -   | -        | -          | MCD, PEP, TXN               |
| Cathie | Growth Innovation  | SELL     | CRSP   | 134 | $54.09   | $7,248.06  | PLTR, PATH, ISRG, TSLA      |

---

## Portfolio Snapshots (Latest, as of cycle close)

| Agent  | Cash       | Holdings Value | Total Value  | Total P&L     | Return %   |
|--------|------------|----------------|--------------|---------------|------------|
| Warren | $35,634.40 | $72,368.86     | $108,003.26  | +$8,003.26    | +8.00%     |
| George | $27,778.36 | $73,248.57     | $101,026.93  | +$1,026.93    | +1.03%     |
| Ray    | $41,981.84 | $54,413.14     | $96,394.98   | -$3,605.02    | -3.61%     |
| Cathie | $29,140.82 | $99,165.13     | $128,305.95  | +$28,305.95   | +28.31%    |

**Combined portfolio**: $433,731.12 - **Combined P&L**: +$33,731.12 (+8.43% blended return).

---

## Guardrail Columns Sanity-Check (V2/V3 Audit)

| Run | Phase    | guardrail_attempts | guardrail_outcome | guardrail_issues | guardrail_failed_output |
|-----|----------|-------------------:|-------------------|------------------|-------------------------|
| 817 | research | 1                  | `first_try`       | NULL             | NULL                    |
| 817 | decision | 1                  | `first_try`       | NULL             | NULL                    |
| 818 | research | 1                  | `first_try`       | NULL             | NULL                    |
| 818 | decision | 1                  | `first_try`       | NULL             | NULL                    |
| 819 | research | 1                  | `first_try`       | NULL             | NULL                    |
| 819 | decision | 1                  | `first_try`       | NULL             | NULL                    |
| 820 | research | 1                  | `first_try`       | NULL             | NULL                    |
| 820 | decision | 1                  | `first_try`       | NULL             | NULL                    |

**Verdict**: PASS - 8/8 phase rows clean. All `guardrail_attempts=1`, all `guardrail_outcome='first_try'`, all `guardrail_issues=NULL`, all `guardrail_failed_output=NULL`. V2/V3 persistence path intact end-to-end.

---

## Current Holdings

### Warren (10 positions, account 1) - HOLD, no change this cycle
| Symbol | Qty | Avg Price | Cost Basis  |
|--------|-----|-----------|-------------|
| ADP    | 29  | $218.35   | $6,332.15   |
| BRK.B  | 36  | $479.95   | $17,278.22  |
| CSCO   | 52  | $119.57   | $6,217.64   |
| CSX    | 138 | $45.65    | $6,299.70   |
| JNJ    | 26  | $230.69   | $5,997.94   |
| LMT    | 12  | $520.07   | $6,240.84   |
| MRK    | 63  | $111.92   | $7,050.96   |
| ORCL   | 26  | $232.28   | $6,039.28   |
| V      | 18  | $333.12   | $5,996.16   |
| WMT    | 51  | $121.04   | $6,173.04   |

### George (10 positions, account 2) - post-C-buy (final slot filled)
| Symbol | Qty | Avg Price | Cost Basis  |
|--------|-----|-----------|-------------|
| ALB    | 42  | $160.35   | $6,734.70   |
| C      | 48  | $143.06   | $6,866.88   |
| CF     | 58  | $114.40   | $6,635.20   |
| FCX    | 179 | $69.62    | $12,461.70  |
| FNV    | 30  | $225.38   | $6,761.40   |
| NEM    | 68  | $103.79   | $7,057.72   |
| NOC    | 13  | $521.54   | $6,780.02   |
| NTR    | 122 | $65.03    | $7,933.66   |
| SLB    | 139 | $48.09    | $6,684.51   |
| XOM    | 48  | $147.90   | $7,099.20   |

### Ray (9 positions, account 3) - post-PG-sell
| Symbol | Qty | Avg Price | Cost Basis  |
|--------|-----|-----------|-------------|
| ADP    | 28  | $218.35   | $6,113.80   |
| DUK    | 51  | $124.97   | $6,373.47   |
| MCD    | 22  | $278.65   | $6,130.30   |
| MDT    | 72  | $83.32    | $5,999.04   |
| O      | 106 | $59.91    | $6,350.46   |
| TRV    | 20  | $301.53   | $6,030.60   |
| VZ     | 139 | $45.37    | $6,306.43   |
| WM     | 25  | $228.77   | $5,719.25   |
| XOM    | 43  | $147.53   | $6,343.79   |

### Cathie (9 positions, account 4) - post-CRSP-sell
| Symbol | Qty | Avg Price | Cost Basis  |
|--------|-----|-----------|-------------|
| ARM    | 31  | $213.27   | $6,611.37   |
| ASML   | 7   | $1,658.87 | $11,612.08  |
| CRWD   | 10  | $731.00   | $7,310.00   |
| DDOG   | 36  | $227.34   | $8,184.24   |
| GOOGL  | 33  | $318.28   | $10,503.24  |
| META   | 9   | $566.98   | $5,102.82   |
| MSFT   | 11  | $424.62   | $4,670.82   |
| NVDA   | 135 | $183.91   | $24,827.85  |
| SNOW   | 31  | $232.33   | $7,202.23   |

---

## Detailed Run Data

### Run 817: Ray (Risk Parity)

**Started**: 2026-06-21 13:25:18 UTC | **Completed**: 2026-06-21 13:26:19 UTC (61.5s)
**Status**: COMPLETED

#### Research Phase (39,262 ms)
**Candidates**: JNJ, KO, EMR

**Tool Calls** (7):
1. `brave_web_search(query="Johnson & Johnson dividend aristocrat beta dividend yield 2026 profile", count=5)`
2. `brave_web_search(query="JNJ beta Yahoo Finance Johnson & Johnson beta dividend yield Yahoo Finance", count=5)`
3. `brave_web_search(query="Coca-Cola KO beta dividend yield 2026 dividend aristocrat profile beta 5y Yahoo Finance KO", count=5)`
4. `brave_web_search(query="Emerson Electric EMR dividend aristocrat beta dividend yield 2026 profile low beta", count=5)`
5. `lookup_price_tool(symbol="JNJ")`
6. `lookup_price_tool(symbol="KO")`
7. `lookup_price_tool(symbol="EMR")`

**Research Notes**:
> I selected Johnson & Johnson (JNJ), Coca-Cola (KO), and Emerson Electric (EMR) as candidates that fit a Risk-Parity/all-weather tilt: all are long track-record, low-beta, dividend-paying companies (Dividend Aristocrats/consistent payers) that provide defensive income and lower portfolio volatility across economic regimes. JNJ offers healthcare diversification and low market beta with a ~2.2-2.4% yield; KO adds consumer-staples beverage exposure with stable cash flows and ~2.6% yield; EMR is an industrial/dividend aristocrat that brings lower correlation to consumer and energy holdings while preserving a defensive income profile.
>
> These names help rebalance risk by adding low-volatility, high-quality cash-flow businesses across healthcare, consumer staples, and industrials - reducing concentration in utilities/energy/REITs and improving performance potential in recession/deflation scenarios while still offering inflation resilience via pricing power in KO and EMR.

**Web Sources**:
- [Johnson & Johnson (JNJ) Stock Price, News, Quote & History - Yahoo Finance](https://finance.yahoo.com/quote/JNJ/)
- [Dividend Aristocrats In Focus: Johnson & Johnson - Sure Dividend](https://www.suredividend.com/dividend-aristocrats-jnj/)
- [Johnson & Johnson (JNJ) Dividend History, Dates & Yield - StockAnalysis](https://stockanalysis.com/stocks/jnj/dividend/)
- [The Coca-Cola Company (KO) Stock Price, News, Quote & History - Yahoo Finance](https://finance.yahoo.com/quote/KO/)
- [The Coca-Cola Company (KO) Dividend History, Dates & Yield - StockAnalysis](https://stockanalysis.com/stocks/ko/dividend/)
- [The Coca-Cola Company (KO) Dividend Summary, Yield, History & Payouts | Seeking Alpha](https://seekingalpha.com/symbol/KO/dividends/scorecard)
- [Emerson Electric (EMR) Dividend Yield 2026, Date & History - MarketBeat](https://www.marketbeat.com/stocks/NYSE/EMR/dividend/)
- [Dividend Aristocrats In Focus: Emerson Electric - Sure Dividend](https://www.suredividend.com/dividend-aristocrats-emr/)
- [Emerson Electric Co. (EMR) Dividend History, Dates & Yield - StockAnalysis](https://stockanalysis.com/stocks/emr/dividend/)

**Portfolio Context**: Balance $35,816.26, 10 positions (WM, PG, VZ, TRV, XOM, DUK, O, MDT, ADP, MCD).

#### Decision Phase (20,712 ms)
**Decision**: SELL PG x41

**Reasoning**:
- **Research**: Market Analyst candidates: JNJ (price $228.39; trailing P/E ~22; yield ~2.2-2.4%) - adds healthcare but overlaps existing MDT; KO (price $79.39; trailing P/E mid-20s; yield ~2.6%) - beverage franchise offers orthogonal, low-beta cash flows and best marginal diversification versus portfolio staples; EMR (price $150.66) - industrial dividend aristocrat that lowers correlation to consumer/energy sleeves. I sell PG because it perpetuates staples concentration that KO aims to reduce, and JNJ would increase healthcare overlap with MDT; selling PG creates capacity to add the candidate that most improves risk-adjusted diversification while respecting the 15%/$5,372.44 position cap.
- **Portfolio**: Cash: $35,816.26; Positions: 10/10 (WM, PG 41@150.41, VZ, TRV, XOM, DUK, O, MDT, ADP, MCD). Selling PG (41 shares) frees one position slot and reduces staples overlap vs. KO/PEP/PG cluster while modestly increasing cash to fund a future buy within the $5,372.44 per-position cap.
- **Historical**: Recent trade history for PG shows high churn (26 trades over 90 days with repeated buys/sells and mixed pattern), currentPosition 41 shares avg cost $144.37 - indicates low conviction and limited marginal diversification benefit versus other staples candidates.

**Rationale**: Reduce consumer-staples concentration and free the 10th slot for a lower-correlation defensive candidate later (KO/JNJ/EMR); PG has been actively churned and is the marginal holding with limited incremental diversification.

**Decision Tool Calls** (1):
1. `get_symbol_trade_history(symbol="PG")`

#### Execution
**Trade**: SELL 41 shares PG @ $150.38 = $6,165.58 (trade_id 653)

---

### Run 818: George (Contrarian Macro)

**Started**: 2026-06-21 13:25:18 UTC | **Completed**: 2026-06-21 13:26:23 UTC (65.4s)
**Status**: COMPLETED

#### Research Phase (41,974 ms)
**Candidates**: CCJ, C, LNG

**Tool Calls** (7):
1. `brave_web_search(query="uranium market tightening June 2026 Reuters Cameco CCJ uranium tightness 2026", count=5)`
2. `brave_web_search(query="Citigroup valuation 2026 market outlook June 2026 Reuters Citi 2026 valuation contrarian buy the dip June 2026", count=5)`
3. `brave_web_search(query="Reuters Citigroup outlook 2026 earnings 2026 Citigroup valuation Reuters June 2026 'Citigroup' Reuters '2026'", count=10)`
4. `brave_web_search(query="Cheniere LNG tight global LNG markets 2026 Reuters June 2026 'Cheniere' natural gas exports 2026 Reuters 'LNG' 2026 tight markets", count=10)`
5. `lookup_price_tool(symbol="CCJ")`
6. `lookup_price_tool(symbol="C")`
7. `lookup_price_tool(symbol="LNG")`

**Research Notes**:
> Macro-driven, contrarian shortlist: 1) Cameco (CCJ) - a direct play on a tightening global uranium market as utilities and funds lock up supply; asymmetric upside if term contracts and prices continue to re-rate producers. 2) Citigroup (C) - undervalued large bank with improving earnings, rising trading/net interest income and a turnaround narrative that the market may be underappreciating if volatility and rates stay supportive. 3) Cheniere Energy (LNG) - U.S. LNG exporter positioned to benefit from periodic global gas tightness and higher export margins; a commodity/energy export lever that complements existing oil/minerals exposure.
>
> These candidates fit a contrarian macro posture: exposure to structural commodity dislocations (uranium, LNG) and a beaten-down/under-appreciated financial name with macro sensitivity to rates and volatility. Each idea is selected for asymmetric upside vs. current pricing and for portfolio diversification across macro vectors (nuclear fuel cycle, global gas flows, banking/credit cycle).

**Web Sources**:
- [Is the US uranium market about to go nuclear in 2026? | Reuters](https://www.reuters.com/markets/commodities/is-us-uranium-market-about-go-nuclear-2026-2026-01-14/)
- [Uranium Price Update: Q1 2026 in Review | INN](https://investingnews.com/uranium-forecast/)
- [Citi profit beats estimates as market volatility lifts trading revenue | Reuters](https://www.reuters.com/business/finance/citi-profit-jumps-42-market-volatility-lifts-trading-revenue-2026-04-14/)
- [Citigroup (C) earnings 1Q 2026 | CNBC](https://www.cnbc.com/2026/04/14/citigroup-c-earnings-1q-2026.html)
- [Cheniere reports Q1 loss but raises 2026 outlook on higher LNG output, margins | Reuters](https://www.reuters.com/business/energy/cheniere-energy-posts-first-quarter-loss-2026-05-07/)
- [What excites and worries LNG exporters in 2026 | Reuters](https://www.reuters.com/markets/commodities/what-excites-worries-lng-exporters-2026-2026-01-16/)

**Portfolio Context**: Balance $34,645.24, 9 positions (XOM, FNV, SLB, NTR, NEM, CF, FCX, ALB, NOC).

#### Decision Phase (21,995 ms)
**Decision**: BUY C x48

**Reasoning**:
- **Research**: Market Analyst candidates: CCJ ($106.49) - uranium tightening thesis (Reuters: US uranium market tightening; INN uranium updates); C ($143.06) - undervalued large bank with rising trading/NII and a turnaround narrative (Reuters: Citi profit jumps 42% on trading; CNBC 1Q26 earnings coverage); LNG ($227.03) - Cheniere exposed to periodic global gas tightness but increases commodity exposure (Reuters: Cheniere raised 2026 outlook). I choose C over CCJ and LNG because CCJ/LNG would further concentrate the portfolio in commodity price risk despite attractive asymmetry; C provides macro diversification into a rate/volatility-sensitive financial with recent fundamental beat and clearer rerating pathway, while complying with position-sizing and cash constraints (total_cost $6,866.88 <= $6,929.05 and <= $34,645.24).
- **Portfolio**: Cash $34,645.24; positions 9/10. Buying 48 C shares at $143.06 = $6,866.88, which fits the max_position_value $6,929.05 and leaves cash for liquidity; occupies final slot and reduces heavy commodity/energy concentration in the book.
- **Historical**: Recent trades show a short rotation in C: bought 59 shares at $134.73 (2026-06-10) then sold 59 at $135.06 the same day - no current C position. Sector note: banks have recently benefited from trading volatility and rising NII (see Reuters/CNBC coverage).

**Rationale**: Add Citigroup as a contrarian diversification: improving trading and net interest income with upside if rates/volatility stay supportive, offering asymmetric rerating vs. further commodity concentration.

**Decision Tool Calls** (1):
1. `get_symbol_trade_history(symbol="C")`

#### Execution
**Trade**: BUY 48 shares C @ $143.06 = $6,866.88 (trade_id 654)

---

### Run 819: Warren (Value Investor)

**Started**: 2026-06-21 13:25:18 UTC | **Completed**: 2026-06-21 13:26:34 UTC (76.2s)
**Status**: COMPLETED

#### Research Phase (52,005 ms)
**Candidates**: MCD, PEP, TXN

**Tool Calls** (6):
1. `brave_web_search(query="McDonald's valuation ROE free cash flow 2026 undervalued moat shareholder friendly capital allocation dividends buyback 2026 news", count=10)`
2. `brave_web_search(query="PepsiCo valuation ROE free cash flow 2026 undervalued moat shareholder friendly capital allocation P/E P/B 2026 news", count=10)`
3. `brave_web_search(query="Texas Instruments TXN ROE free cash flow debt-to-equity undervalued 2026 moat analog semiconductors shareholder friendly buybacks 2026 news", count=10)`
4. `lookup_price_tool(symbol="MCD")`
5. `lookup_price_tool(symbol="PEP")`
6. `lookup_price_tool(symbol="TXN")`

**Research Notes**:
> I screened high-quality, cash-generative businesses with durable moats, multi-year earnings consistency, shareholder-friendly capital allocation, and valuations that look reasonable vs. peers. McDonald's (MCD) offers a franchise-driven moat, strong free cash flow and steady buybacks/dividends; recent coverage shows distributable cash and a modest yield supporting shareholder returns. PepsiCo (PEP) combines powerful brands, high ROE and reliable FCF with a disciplined capital-allocation pivot; valuation metrics and management guidance point to continued cash returns. Texas Instruments (TXN) is a capital-light analog semiconductor leader with double-digit FCF per share guidance, conservative debt, heavy buybacks and a long-term moat in analog/IP and manufacturing scale.
>
> Given the portfolio is at capacity, these names were chosen as candidates to complement or potentially replace existing holdings: MCD/PEP for consumer-staples/defensive exposure with brand moats and stable cash generation (less cyclicality than a pure retailer), and TXN to increase FCF yield and buyback-driven EPS growth. Each candidate shows the hallmarks Warren prefers: strong cash conversion, shareholder-friendly management, durable advantages and valuations that warrant further fundamental review before any trade.

**Web Sources**:
- [Assessing McDonald's (MCD) Valuation After Its New Quarterly Dividend Announcement - Simply Wall St News](https://simplywall.st/stocks/us/consumer-services/nyse-mcd/mcdonalds/news/assessing-mcdonalds-mcd-valuation-after-its-new-quarterly-di/amp)
- [McDonald's Corporation (MCD) Statistics & Valuation - StockAnalysis](https://stockanalysis.com/stocks/mcd/statistics/)
- [PepsiCo Announces Priorities to Enhance Shareholder Value and Provides Preliminary 2026 Financial Outlook - PepsiCo Newsroom](https://www.pepsico.com/newsroom/press-releases/2025/pepsico-announces-priorities-to-enhance-shareholder-value-and-provides-preliminary-2026-outlook)
- [PepsiCo (PEP) Statistics & Valuation - StockAnalysis](https://stockanalysis.com/stocks/pep/statistics/)
- [TI reports first quarter 2026 financial results and shareholder returns - Texas Instruments Investor Relations](https://investor.ti.com/news-releases/news-release-details/ti-reports-first-quarter-2026-financial-results-and-shareholder)
- [Texas Instruments Slashes 2026 CapEx Outlook, Targets $8+ Free Cash Flow Per Share - Yahoo Finance](https://finance.yahoo.com/news/texas-instruments-slashes-2026-capex-101721209.html)

**Portfolio Context**: Balance $35,634.40, 10 positions (CSCO, BRK.B, WMT, JNJ, ORCL, V, ADP, MRK, LMT, CSX).

#### Decision Phase (22,980 ms)
**Decision**: HOLD

**Reasoning**:
- **Research**: Market Analyst candidates: MCD ($278.61) - franchise/franchise-driven moat, steady distributable cash and a modest yield per the analyst; PEP ($142.02) - strong brands, high ROE and reliable FCF with analyst forward P/E ~18 (attractive vs. peers); TXN ($322.86) - capital-light analog leader with guidance for $8+ FCF/share and heavy buybacks but reported mid-to-high-30s P/E (rich). I decline to rotate because: PEP and MCD would materially increase staples exposure and PEP has been recently traded in this account; TXN's valuation reduces margin-of-safety despite strong FCF guidance. Given our value criteria (moat, predictable FCF, conservative valuation) and the position/cash constraints, HOLD is the prudent choice now.
- **Portfolio**: Cash $35,634.40; positions 10/10: CSCO, BRK.B, WMT, JNJ, ORCL, V, ADP, MRK, LMT, CSX. With the roster full and a 15%/position cap (max $5,345.16), I cannot open a new position in MCD/PEP/TXN without first selling an incumbent, which I am not willing to do absent a decisive margin-of-safety advantage.
- **Historical**: Recent activity shows multiple staples rotations (buys/sells of PEP and PG) and a consistent preference to avoid churn; no meaningful TXN trades in the recent 30-day history. Prior decisions favored HOLD when candidates overlapped existing exposures or lacked a clear valuation edge.

**Rationale**: Portfolio is at the 10/10 limit and the per-position cap ($5,345.16) prevents opening a new slot without selling; none of MCD/PEP/TXN offers a clear valuation margin to justify rotating a current high-conviction holding now, so I will HOLD.

**Decision Tool Calls** (0): _(none - HOLD decision skipped trade-history lookup)_

#### Execution
No execution row recorded (HOLD).

---

### Run 820: Cathie (Growth Innovation)

**Started**: 2026-06-21 13:25:18 UTC | **Completed**: 2026-06-21 13:26:49 UTC (90.9s)
**Status**: COMPLETED

#### Research Phase (63,078 ms)
**Candidates**: PLTR, PATH, ISRG, TSLA

**Tool Calls** (10):
1. `brave_web_search(query="Palantir 2026 revenue growth AI platform Q1 2026 Palantir earnings outlook 2026 news", count=5)`
2. `brave_web_search(query="UiPath Q1 2026 revenue growth 2026 automation platform earnings 2026 PATH growth RPA news", count=5)`
3. `brave_web_search(query="Intuitive Surgical Q1 2026 revenue growth da Vinci robotic surgery market share Q1 2026 earnings news ISRG 2026 R&D", count=5)`
4. `brave_web_search(query="Block Q1 2026 revenue growth Square Cash App blockchain fintech Q1 2026 earnings Block Inc SQ 2026 news", count=5)`
5. `lookup_price_tool(symbol="PLTR")`
6. `lookup_price_tool(symbol="PATH")`
7. `lookup_price_tool(symbol="ISRG")`
8. `lookup_price_tool(symbol="SQ")`
9. `brave_web_search(query="Tesla FSD 2026 robotaxi progress 2026 revenue growth Autopilot Tesla 2026 news June 2026", count=5)`
10. `brave_web_search(query="Reuters Tesla robotaxi 2026 FSD approval 2026 Reuters May 2026 Tesla robotaxi news", count=10)`

Plus one trailing `lookup_price_tool(symbol="TSLA")` invocation (totaling 11 tool calls when TSLA price lookup is counted separately, as recorded in `tool_calls`).

**Research Notes**:
> I selected four disruptive-innovation candidates that extend the portfolio's existing AI, compute and platform exposure into application-layer AI, enterprise automation, surgical robotics, and autonomy/robotics. Palantir (PLTR) is a fast-growing AI software platform with outsized U.S. commercial traction and raised FY-2026 guidance after Q1 showing ~85% YoY revenue growth. UiPath (PATH) is repositioning from RPA to agentic automation and has recently beaten revenue expectations while rebuilding ARR momentum. Intuitive Surgical (ISRG) is the leader in surgical robotics with durable recurring revenue, a major upgrade cycle (da Vinci 5/Ion) and high R&D intensity. Tesla (TSLA) remains the highest-conviction autonomy/robotics play - FSD/robotaxi and Optimus robotics are transformative optionalities beyond the EV hardware franchise.
>
> These names complement the portfolio's infrastructure and AI holdings (NVDA, ARM, MSFT, GOOGL, SNOW, DDOG) by adding software-led, application-level AI (PLTR, PATH), robotics in healthcare (ISRG), and end-user autonomous platforms (TSLA). Each candidate represents a distinct path to exponential upside: enterprise AI monetization, automation-driven productivity capture, surgical-robotics TAM expansion, and a potential shift from hardware to AI-as-a-service in mobility and robotics.

**Web Sources**:
- [Palantir (PLTR) Q1 earnings report 2026 | CNBC](https://www.cnbc.com/2026/05/04/palantir-pltr-q1-earnings-report-2026.html)
- [Palantir Reports Q1 2026 U.S. Revenue Growth of 104% Y/Y; Raises FY-2026 Guidance](https://investors.palantir.com/news-details/2026/Palantir-Reports-Q1-2026-U-S--Revenue-Growth-of-104-YY-and-Revenue-Growth-of-85-YY-Raises-FY-2026-Revenue-Guidance-to-71-YY-Growth-and-U-S--Comm-Revenue-Guidance-to-120-YY-Crushing-Consensus-Expectations/)
- [Palantir Q1 FY 2026: 85% revenue growth, stock drops 5.7% | Investing.com](https://www.investing.com/news/company-news/palantir-q1-2026-slides-85-revenue-growth-stock-drops-57-93CH-4674799)
- [UiPath Beats Q1 CY2026 Sales Expectations | Yahoo Finance](https://finance.yahoo.com/markets/stocks/articles/uipath-nyse-path-beats-q1-204216481.html)
- [UiPath Quarterly Results (Investor Relations)](https://ir.uipath.com/financials/quarterly-results)
- [Intuitive Announces First Quarter Earnings | Intuitive Surgical](https://isrg.intuitive.com/news-releases/news-release-details/intuitive-announces-first-quarter-earnings-7)
- [Intuitive Surgical Inc (ISRG) Q1 2026 Earnings Call Highlights | Yahoo Finance](https://finance.yahoo.com/sectors/healthcare/articles/intuitive-surgical-inc-isrg-q1-070409934.html)
- [Tesla's robotaxi rollout features Texas-sized wait times | Reuters](https://www.reuters.com/business/autos-transportation/teslas-robotaxi-rollout-features-texas-sized-wait-times-2026-05-12/)
- [Tesla Q1 2026 Update (Tesla investor PDF)](https://assets-ir.tesla.com/tesla-contents/IR/TSLA-Q1-2026-Update.pdf)

**Portfolio Context**: Balance $21,892.76, 10 positions (NVDA, DDOG, SNOW, CRSP, GOOGL, ASML, CRWD, META, ARM, MSFT).

#### Decision Phase (26,511 ms)
**Decision**: SELL CRSP x134

**Reasoning**:
- **Research**: Market Analyst candidates considered: PLTR (Palantir Q1 2026: ~85% revenue YoY growth; U.S. revenue +104% YoY; raised FY-2026 guidance - Palantir investor release/CNBC), PATH (UiPath: repositioning to agentic automation; recent beats - Yahoo Finance; analyst note: mid-20s software multiple), ISRG (Intuitive Surgical: surgical-robotics leader with da Vinci 5/Ion upgrade cycle, high R&D and premium forward valuation ~mid-40s - Intuitive Q1 release/Yahoo), TSLA (Tesla: FSD/robotaxi and Optimus optionality but execution/capex risk - Reuters; Tesla Q1 2026 update). I prioritize freeing capacity for PLTR (enterprise AI platform with high revenue acceleration and raised guidance) because it best extends our AI stack into application-layer, compounding ARR; PATH overlaps existing enterprise software exposure (MSFT/GOOGL), ISRG is premium/medical-capex intensive, and TSLA carries larger execution/capex optionality.
- **Portfolio**: Cash $21,892.76; positions 10/10 (NVDA, DDOG, SNOW, CRSP, GOOGL, ASML, CRWD, META, ARM, MSFT). Selling 134 CRSP shares will open one position slot and shift exposure from high-binary biotech to enterprise AI application/automation.
- **Historical**: Trade history for CRSP (checked): mixed pattern with prior buys/sells and current holding 134 shares (average cost $51.01) - indicates active trading and realized volatility; CRISPR/genome-editing sector carries classic binary/regulatory commercial risk versus predictable SaaS/recurring models.

**Rationale**: Sell full CRSP position to free a slot and capital for adding an application-layer enterprise AI name (primary candidate: PLTR) - CRSP is high binary/clinical risk and less aligned with the portfolio's core disruptive-AI/robotics mandate.

**Decision Tool Calls** (1):
1. `get_symbol_trade_history(symbol="CRSP")`

#### Execution
**Trade**: SELL 134 shares CRSP @ $54.09 = $7,248.06 (trade_id 655)

---

## Aggregate Statistics - Cycle 817-820

| Metric                                | Value             |
|---------------------------------------|-------------------|
| Total Runs                            | 4                 |
| Successful                            | 4 (100%)          |
| Failed                                | 0                 |
| Total Trades                          | 3 (1 BUY, 2 SELL) |
| HOLD Decisions                        | 1                 |
| Total Capital Deployed (gross)        | $20,280.52        |
| Avg Research Latency                  | 49,080 ms (~49s)  |
| Avg Decision Latency                  | 23,049 ms (~23s)  |
| Avg Research Tool Calls               | 7.5               |
| Combined Portfolio Value              | $433,731.12       |
| Combined P&L                          | +$33,731.12       |
| Blended Return                        | +8.43%            |
| Reasoning Fields Complete             | 4/4               |
| Missing Phases                        | 0 (HOLD legitimately has no execution row) |
| Guardrail rows populated (V2 audit)   | 8/8 (4 research + 4 decision) |
| Guardrail trips this cycle            | 0                 |

---

## Comparison with Previous Report

**Previous**: `TRADING_CYCLE_REPORT_20260620.md` (cycle 07:24 UTC on 2026-06-20, runs 789-792, 3 trades + 1 HOLD)
**Current**: `TRADING_CYCLE_REPORT_20260621.md` (cycle 13:25 UTC on 2026-06-21, runs 817-820, 3 trades + 1 HOLD)

**Comparison caveat**: This cycle ran against an agents image bundling the "agent runner `.run()` deletion" refactor that shipped earlier today via `/req-process-quick` against `tasks/delete-dead-agent-run-methods/DDARM_requirements.md`. The refactor deleted `MarketAnalyst.run()`, `DecisionMaker.run()`, and the `AgentRunResult` dataclass - all dead code with zero production callers. The 06-20 baseline ran on the pre-deletion image. The cycle's job here is to confirm the deletion did not accidentally break anything in the live `phase_runner` code path; pipeline metrics (completion rate, latency, reasoning completeness, guardrails) should match within noise.

| Metric                          | Previous (789-792)     | Current (817-820)      | Status |
|---------------------------------|------------------------|------------------------|--------|
| Completion Rate                 | 4/4 (100%)             | 4/4 (100%)             | OK     |
| Failed Runs                     | 0                      | 0                      | OK     |
| Trades Executed                 | 3 (1 BUY, 2 SELL)      | 3 (1 BUY, 2 SELL)      | OK     |
| HOLD Decisions                  | 1                      | 1                      | OK     |
| Reasoning Fields Complete       | 4/4                    | 4/4                    | OK     |
| Missing Phases                  | 0                      | 0                      | OK     |
| Avg Research Tool Calls         | 6.5                    | 7.5                    | OK (+1.0, within normal agent-discretion range) |
| Avg Research Latency            | ~54s                   | ~49s                   | OK (-5s, faster) |
| Avg Decision Latency            | ~27s                   | ~23s                   | OK (-4s, faster) |
| Avg Cycle Duration              | ~83s (71-102s range)   | ~74s (61-91s range)    | OK (-9s, faster overall) |
| Combined Portfolio Value        | $433,727.31            | $433,731.12            | +$3.81 (essentially flat; market-dependent) |
| Combined P&L                    | +$33,727.31            | +$33,731.12            | +$3.81 (market-dependent) |
| Blended Return                  | +8.43%                 | +8.43%                 | OK (flat) |
| Guardrail rows populated        | 8/8                    | 8/8                    | OK     |
| Guardrail trips                 | 0                      | 0                      | OK     |
| V2/V3 columns populated         | Yes                    | Yes                    | OK     |

### Regressions Found

**None.** All system-level checks passed. Completion rate, failure count, trade count, HOLD count, reasoning-field completeness, missing-phase count, and guardrail population all match the 06-20 baseline exactly. Latency moved *down* across all three categories (research, decision, total cycle) - that's an improvement, not a regression. The +1.0 drift in `avg_research_tool_calls` (6.5 -> 7.5) is agent-discretion (Cathie ran 4 candidates instead of 5 but still issued 10+ tool calls; Ray issued one query per candidate plus a follow-up; George burned a fourth web search refining a Citi-specific query) - every research note still cites multiple distinct sources and all reasoning fields are populated.

### Style Distribution
- Ray (Risk Parity) - SELL PG (trim staples concentration; free slot for KO/JNJ/EMR rotation next cycle)
- George (Contrarian Macro) - BUY C (fill 10th slot with rate/volatility-sensitive financial; diversify from commodity overweight)
- Warren (Value Investor) - HOLD (10/10 at cap; MCD/PEP/TXN all overlap or lack margin-of-safety)
- Cathie (Growth Innovation) - SELL CRSP (rotate out of binary biotech to free slot for AI application-layer name)

---

## Closing Note

All four agents completed their pipelines end-to-end on the new agents image (pod `agents-57b9f6767d-wp5c6`, SHA `c4dbf26548c5e48055fec282fc71da4574bd6f1cf2508d9adbbbdd97a6d942ef`). The "agent runner `.run()` deletion" refactor that shipped this morning - removing `MarketAnalyst.run()`, `DecisionMaker.run()`, and the `AgentRunResult` dataclass - is verified by this cycle: completion rate (4/4), failure count (0), reasoning-field completeness (4/4), guardrail population (8/8), and missing-phase count (0) all match the 06-20 baseline exactly. Pre-flight log evidence already confirmed the new code path was active (`phase_runner.cycle` 48 lines + `phase_runner._telemetry` 16 lines in the agents pod logs, zero ERRORs beyond the known Finnhub 404 baseline), and the database state corroborates: every run wrote complete research/decision phases with `guardrail_outcome='first_try'`, the three trade-emitting runs persisted their execution rows cleanly, and the HOLD run legitimately produced no execution row. The +1.0 drift in `avg_research_tool_calls` is agent-discretion noise (Cathie's 10-call PLTR/PATH/ISRG/TSLA sweep is structurally similar to her 10-call sweep on 06-20), not a pipeline regression. Latency improved slightly across all three categories. Nothing in the live `phase_runner` code path appears to have been affected by the dead-code deletion; the refactor is safe in staging.
